Covalent drug – An emerging framework for targeted drug development
Authors:
- Ritesh P. BholeRBRitesh P. Bhole
- Govinda O. JoshiGJGovinda O. Joshi
- Harshad S. KapareHKHarshad S. Kapare
- Rupesh V. ChikhaleRCRupesh V. Chikhale
- Somdatta ChaudhariSCSomdatta Chaudhari
Open Access
- 24 June 2024
- journal article
- research article
- Published by Elsevier in Results in Chemistry
- Vol. 8
Abstract
No abstract availableKeywords
This publication has 127 references indexed in Scilit:
- Discovery of a Cell‐Active SuTEx Ligand of Prostaglandin Reductase 2ChemBioChem, 2021
- Efficacy and Safety of PF‐06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate‐to‐Severe Rheumatoid Arthritis and an Inadequate Response to MethotrexateArthritis & Rheumatology, 2020
- Biocompatible SuFEx Click Chemistry: Thionyl Tetrafluoride (SOF4)‐Derived Connective Hubs for Bioconjugation to DNA and ProteinsAngewandte Chemie International Edition, 2019
- Targeted Covalent Inhibitors for Drug DesignAngewandte Chemie International Edition, 2016
- Panniculitis in Patients Undergoing Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid LeukemiasJAMA Oncology, 2015
- Sulfur(VI) Fluoride Exchange (SuFEx): Another Good Reaction for Click ChemistryAngewandte Chemie International Edition, 2014
- Selective Inhibition of Mutant Ras Protein through Covalent BindingAngewandte Chemie International Edition, 2014
- COVALENT ENZYME INHIBITION IN DRUG DISCOVERY AND DEVELOPMENT2013
- A Bond by Any Other NameAngewandte Chemie International Edition, 2010
- Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine KinaseChemMedChem, 2006